Incidence of Biofilm Formation in ET Tube and Correlation with Occurrence of VAP in a Tertiary Care ICU

Abhay Uppe^1, , Deepak Gupta¹, Sayli Sawant¹ and Girija Nair¹

¹Department of Pulmonary Medicine, DY Patil School of Medicine, Nerul, Navi Mumbai - 400706

Cite this paper:
Abhay Uppe, Deepak Gupta, Sayli Sawant and Girija Nair. Incidence of Biofilm Formation in ET Tube and Correlation with Occurrence of VAP in a Tertiary Care ICU. American Journal of Infectious Diseases and Microbiology. 2019; 7(2):65-72. doi: 10.12691/ajidm-7-2-2

Abstract

Introduction: VAP is one of the most frequent hospital-acquired infections occurring in mechanically ventilated patients and is associated with increased mortality, morbidity, and health-related costs. Bacterial biofilm has been observed universally on the surface of endotracheal tubes in mechanically ventilated patients. Some data show a good concordance between bacterial colonization of the airway and microbial findings in the biofilm. Even the same microorganisms causing VAP could be found in the ETT biofilm leading to the potential implication of biofilm in the genesis of VAP. Aims and Objectives: The objective was to investigate the involvement of ETT biofilm in VAP pathogenesis. Materials and Methods: This observational descriptive study was conducted in Department of Pulmonary Medicine, D.Y Patil Hospital, Nerul, Navi Mumbai. Approval of Institutional Ethics Committee was taken before start of the study. A written signed informed consent was taken prior to enrolling the subjects in the study. Patients requiring mechanical ventilation for at least 24 hours were included in the study. The following data were recorded in a standardized form: age and sex of the patient, cause of mechanical ventilation, duration of ventilation, manoeuvres to prevent VAP, the occurrence or not of nosocomial pneumonia, together with data of pathogen isolated in respiratory samples and/or ETT biofilm, antibiotic therapy and sensitivity patterns. Statistical Method: Descriptive and analytical statistics was done. The data was analyzed using statistical software (IBM SPSS V20.1, IBM Corporation, Armonk, NY, USA). The results are expressed as mean ± standard deviation and proportions. Categorical variables were compared using chi-square tests. The statistical significance was determined at p<0.05.Results: A total of 55 subjects fulfilling the inclusion criteria were participated in the study. The mean age of the study population was 46.56 ± 19.79 with a range of 18 to 87 years. There were 23 (41.8%) males and 32 (58.2%) female’s subjects in the study population. The patients were intubated for mainly three reasons – AHF, ARF and CVA. The diagnosis of the ventilated patients was as follows – pneumonia (25.4%), ARDS (18.2%), cerebral stroke (16.4%), septic shock (16.4%), hemorrhagic shock (9.1%), cardiac arrest (7.3%), cardiopulmonary failure (5.4%) and interstitial lung disease (1.8%). The mean duration of intubation was 10.23 ± 1.55, ICU days was 13.45± 1.34 and hospital days was 19.72 ± 2.84. Out of the 55 ventilated patients, 9 (16.3%) patients developed VAP. Biofilm was found positive in 30 (54.5%) patients. In the present study the three most common organisms found in ET tube were Acinetobacter (23.6%), klebsiella (18.2%), E.Coli (7.3%). The other organisms found were Pseudomonas (7.3%), Candida Albicans (3.6%) and staphylococcus (1.8%). The incidence of VAP development in biofilm positive cases was 30%. Conclusion: Biofilms are highly organized microbial communities which in vivo play an important part in evading the defence mechanism and obstinate the antimicrobial therapy. The precise link between biofilm productions in mechanically ventilated patients is still obscure apart from some limited studies which have described role of a specific pathogen or virulence factor. The present study, thus, showed that majority of the pathogens isolated possessed capability to produce biofilm.

Keywords:
VAP EET biofilm nosocomial pneumonia hospital acquired pneumonia

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Kalanuria AA, Zai W, Mirski M, et al. Ventilator- associated pneumonia in the ICU. Crit Care 2014; 18:208.
[2]	Jones RN. Microbial etiologies of hospital- acquired bacterial pneumonia and ventilator- associated bacterial pneumonia. Clin Infect Dis 2010; 51: S81-S87.
[3]	Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: Its relevance to developing effective strategies for prevention. Resp Care 2005; 50:725-741.
[4]	Hunter JD. Ventilator associated pneumonia. BMJ 2012; 344:3225.
[5]	Afshari A, Pagani L, Harbarth S. Year in review 2011: Critical Care Infection. Crit Care 2012; 16: 242.
[6]	Shahrokhi E, Hasani A, Ansarin K, Mikaili H, Hasani A, Aghazadeh M, et al. Bacterial Biofilm in Ventilator-Associated Pneumonia: A Clinical Concern. Journal of Research in Medical and Dental Science 2018; 6(4): 46-51.
[7]	Craven DE, Steger KA: Epidemiology of nosocomial pneumonia. New perspectives on an old disease. Chest 1995, 108: 1S-16S.
[8]	Rello J, Sonora R, Jubert P, Artigas A, Rue M, Valles J: Pneumonia in intubated patients: role of respiratory airway care. Am J Respir Crit Care Med 1996, 154: 111-115.
[9]	Pneumatikos IA, Dragoumanis CK, Bouros DE: Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. Anesthesiology 2009, 110: 673-680.
[10]	Gil-Perotin S, Ramirez, P Marti V, Sahuquillo JM, Gonzalez E, Calleja I, Menendez R, BonastreJ.Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Critical Care 2012 16: R93.
[11]	Costerton JW: Introduction to biofilm. Int J Antimicrob Agents 1999, 11: 217-221, discussion 237-239.
[12]	Donlan RM: Biofilms: microbial life on surfaces. Emerg Infect Dis 2002, 8: 881-890.
[13]	Raad I: Intravascular-catheter-related infections. Lancet 1998, 351: 893-898.
[14]	Nickel JC, Costerton JW, McLean RJ, Olson M: Bacterial biofilms: influence on the pathogenesis, diagnosis and treatment of urinary tract infections. J Antimicrob Chemother 1994, 33 (Suppl A): 31-41.
[15]	Donlan RM: Biofilms and device-associated infections. Emerg Infect Dis 2001, 7:277-281.
[16]	Feldman C, Kassel M, Cantrell J, Kaka S, Morar R, Goolam Mahomed A, Philips JI: The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J 1999, 13:546-551.
[17]	Zur KB, Mandell DL, Gordon RE, Holzman I, Rothschild MA: Electron microscopic analysis of biofilm on endotracheal tubes removed from intubated neonates. Otolaryngol Head Neck Surg 2004, 130: 407-414.
[18]	Sottile FD, Marrie TJ, Prough DS, Hobgood CD, Gower DJ, Webb LX, Costerton JW, Gristina AG: Nosocomial pulmonary infection: possible etiologic significance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986, 14: 265-270.
[19]	Rello J, Gallego M, Mariscal D, Sonora R, Valles J: The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 15:196-200.
[20]	Torres A, Martos A, Puig de la Bellacasa J, Ferrer M, el-Ebiary M, Gonzalez J, Gene A, Rodriguez-Roisin R: Specificity of endotracheal aspiration, protected specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. Am Rev Respir Dis 1993, 147:952-957.
[21]	Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
[22]	Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
[23]	Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G: Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 1987, 13:342-346.
[24]	Rello J, Diaz E: Pneumonia in the intensive care unit. Crit Care Med 2003, 31:2544-2551.
[25]	Luna CM, Aruj P, Niederman MS, Garzon J, Violi D, Prignoni A, Rios F, Baquero S, Gando S: Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006, 27:158-164.
[26]	Visscher S, Schurink CA, Melsen WG, Lucas PJ, Bonten MJ: Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. Intensive Care Med 2008, 34:692-699.
[27]	Rello J, Mariscal D, March F, Jubert P, Sanchez F, Valles J, Coll P: Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 1998, 157: 912-916.
[28]	Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator- associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598.
[29]	Ioanas M, Ferrer M, Cavalcanti M, Ferrer R, Ewig S, Filella X, de laBellacasa JP, Torres A: Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. Crit Care Med 2004, 32: 938-945.
[30]	Hortal J, Muñoz P, Cuerpo G, et al. Ventilator-associated pneumonia in patients undergoing major heart surgery: An incidence study in Europe. Crit Care 2009; 13:R80.
[31]	Charles MP, Kali A, Easow JM, et al. Ventilator- associated pneumonia. Australasian Med J 2014; 7:334-344.
[32]	Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010; 51: S48-S53.
[33]	Akers KS, Chaney C, Barsoumian A, et al. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii- calcoaceticus complex. J Clin Microbiol 2010; 48: 1132-1138.
[34]	Ahmed W. Microorganisms related with ventilator associated pneumonia (VAP) and their antibiotic sensitivity pattern. J Rawalpindi Med Coll 2014; 18:45-48.
[35]	Tsakiridou E, Makris D, Daniil Z, et al. Acinetobacter baumannii infection in prior ICU bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. Biomed Res Int 2014; 2014: 193516.
[36]	Ahsan AA, Barai L, Faruq MO, et al. Antibiotic resistance pattern among bacteria causing ventilator associated pneumonia in an intensive care unit of Bangladesh. Bangladesh Crit Care J 2016; 4: 69-73.
[37]	Golia S, Sangeetha K, Vasudha C. Microbial profile of early and late onset ventilator associated pneumonia in the intensive care unit of a tertiary care hospital in Bangalore, India. J Clin Diag Res 2013; 7:2462.
[38]	Khezri HD, Gorji MAH, Morad A, et al. Comparison of the antibacterial effects of matrica&Persica and chlorhexidine gluconate mouthwashes in mechanically ventilated ICU patients: A double blind randomized clinical trial. Rev ChilenaInfectol 2013; 30: 368-373.
[39]	Costerton JW, Stewart PS, Greenberg EP, et al. Bacterial biofilms: A common cause of persistent infections. Sci 1999; 284: 1318-1322.
[40]	Sottile FD, Marrie TJ, Prough DS, Hobgood CD, Gower DJ, Webb LX, et al. Nosocomial pulmonary infection: possible etiologic sig- nificance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986; 14(4): 265-270.
[41]	Berra L, Curto F, Li Bassi G, Laquerriere P, Pitts B, Baccarelli A, Kolobow T. Antimicrobial-coated endotracheal tubes: an experimen- tal study. Intensive Care Med 2008; 34(6): 1020-1029.
[42]	Ramirez P, Ferrer M, Torres A. Prevention measures for ventilator- associated pneumonia: a new focus on the endotracheal tube. CurrOpin Infect Dis 2007; 20(2): 190-197.
[43]	Berra L, Kolobow T, Laquerriere P, Pitts B, Bramati S, Pohlmann J, et al. Internally coated endotracheal tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: a clinical trial. Inten- sive Care Med 2008; 34(6): 1030-1037.
[44]	Malacarne P, Corini M, Maremmani P, Viaggi B, Verdigi S: Diagnostic characteristics of routine surveillance cultures of endotracheal aspirate samples in cases of late-onset ventilator-associated pneumonia due to Acinetobacter baumannii. Infect Control Hosp Epidemiol 2007, 28:867-869.
[45]	Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J: Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 2009, 43:28-35.
[46]	Depuydt P, Benoit D, Vogelaers D, Decruyenaere J, Vandijck D, Claeys G, Verschraegen G, Blot S: Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Med 2008, 34:675-682.
[47]	Jung B, Sebbane M, Chanques G, Courouble P, Verzilli D, Perrigault PF, Jean- Pierre H, Eledjam JJ, Jaber S: Previous endotracheal aspirate allows guiding the initial treatment of ventilator-associated pneumonia. Intensive Care Med 2009, 35:101-107.
[48]	Gil-Perotin S, Ramirez, P Marti V, Sahuquillo JM, Gonzalez E, Calleja I, Menendez R, BonastreJ.Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Critical Care 2012 16:R93.
[49]	Sirvent JM, Torres A, Vidaur L, Armengol J, de Batlle J, Bonet A: Tracheal colonisation within 24 h of intubation in patients with head trauma: risk factor for developing early-onset ventilator-associated pneumonia. Intensive Care Med 2000, 26:1369-1372.
[50]	Bonten MJ, Kollef MH, Hall JB: Risk factors for ventilator-associated pneumonia: from epidemiology to patient management. Clin Infect Dis 2004, 38:1141-1149.
[51]	Cairns S, Thomas JG, Hooper SJ, Wise MP, Frost PJ, Wilson MJ, et al. Molecular analysis of microbial communities in endotracheal tube biofilms. PLoS One. 2011; 6(3): e14759.
[52]	Perkins SD, Woeltje KF, Angenent LT. Endotracheal tube biofilm inoculation of oral flora and subsequent colonization of opportunistic pathogens. Int J Med Microbiol 2010; 300(7): 503-511.
[53]	Cairns S, Thomas JG, Hooper SJ, Wise MP, Frost PJ, Wilson MJ, et al. Molecular analysis of microbial communities in endotracheal tube biofilms. PLoS One; 6(3): e14759.
[54]	Berra L, Sampson J, Fumagalli J, Panigada M, Kolobow T. Alternative approaches to ventilator-associated pneumonia prevention. Minerva Anestesiol. 2011; 77(3): 323-333.
[55]	Deem S, Treggiari MM. New endotracheal tubes designed to prevent ventilator-associated pneumonia: do they make a difference? Respir Care 2010; 55(8): 1046-1055.
[56]	Lorente L, Blot S, Rello J. New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med 2010; 182(7): 870-876.
[57]	Pacheco-Fowler V, Gaonkar T, Wyer PC, Modak S. Antiseptic impregnated endotracheal tubes for the prevention of bacterial colonization. J Hosp Infect 2004; 57(2): 170-174.
[58]	Olson ME, Harmon BG, Kollef MH. Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest 2002; 121(3): 863-870.
[59]	Berra L, Coppadoro A, Bittner EA, Kolobow T, Laquerriere P, Pohl- mann JR, et al. A clinical assessment of the Mucus Shaver: a device to keep the endotracheal tube free from secretions. Crit Care Med 2012; 40(1): 119-124.